Trilaciclib, a CKD4/6 inhibitor, reduces chemotheraphy-induced toxicity in patients being treated for small-cell lung cancer. Trilaciclib’s developer, G1 Therapeutics, makes the drug available in the U.S. under Expanded access while the FDA considers its New Drug Application (NDA). An approval decision on the NDA is expected by February 15, 2021. On February 12, 2021, the FDA approved trilaciclib (brand name Cosela) as a treatment to reduce the frequency of chemotherapy-induced myelosuppression for patients receiving certain types of chemotherapy for extensive-stage small-cell lung cancer.